---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: XOMA 358 First-in-Human study"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: XOMA 358 First-in-Human study. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 19 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence/xoma-358-first-in-human-study"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: XOMA 358 First-in-Human study

<a id="heading-3.1.5"></a>

## 3.1.5 XOMA 358 First-in-Human Study

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Primary and secondary objectives

> “The primary objective was to assess safety and tolerability, and secondary objectives included PK and PD analyses.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.1-2"></a>

#### Objectives stated at study start

> “The study also will explore the biologic effects of ascending single IV doses of XOMA 358 on glucose and insulin levels as well as insulin sensitivity.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### First participant dosed in October 2014

> “today announced it has initiated dosing in its Phase 1 study exploring the safety and tolerability of single intravenous doses (IV) of XOMA 358, the lead compound from the Company's XMetD program, in healthy volunteers.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

> “We launched clinical development activities for XOMA 358 in October 2014, with the first patient dosed in our Phase 1 safety and tolerability study.”

Source: [XOMA Form 10-K (2015)](https://www.sec.gov/Archives/edgar/data/791908/000114036115011358/form10k.htm)

<a id="topic-3.1.5.2-2"></a>

#### Completion and presentation in 2015

> “In March 2015, we announced that we successfully completed a Phase 1 clinical study of XOMA 358, a fully human, allosteric monoclonal antibody that attenuates both the binding of insulin to its receptor and downstream insulin signaling.  We have presented the data at the ENDO 2015 meeting and at the American Diabetes Association’s 75th Scientific Sessions.”

Source: [XOMA Form 10-K (2016)](https://www.sec.gov/Archives/edgar/data/791908/000156459016014295/xoma-10k_20151231.htm)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Double-blind, placebo-controlled, single ascending dose

> “A double-blind, placebo-controlled, single-ascending-dose study was performed with 29 healthy adult males”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.3-2"></a>

#### Dose escalation by cohort

> “Individual cohorts were administered XOMA 358 doses of 0.1, 0.3, 1, and 3 mg/kg or placebo, with dose escalation based on review of safety and pharmacokinetic data from each cohort.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Single intravenous infusion of placebo or 0.1 to 9 mg/kg

> “randomized to intravenous infusion of placebo or X358 at 0.1-, 0.3-, 1-, 3-, 6-, or 9-mg/kg dose levels.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.5-2"></a>

#### Insulin infusion challenge at 3 mg/kg

> “Subjects who were given a single administration of XOMA 358 at 3 mg/kg were infused with insulin before and 2, 3 and 5 days after dosing.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Purpose of the first-in-human study: safety, pharmacokinetics, and dose selection

> “In addition to showing the safety and pharmacokinetics of this unique antibody, the study is designed to show relevant biologic activity and inform dose selection for Phase 2 trials.”

Source: [XOMA (2014)](https://investors.xoma.com/news-events/press-releases/detail/258/xoma-launches-xoma-358-clinical-development)

<a id="topic-3.1.5.6.1-2"></a>

##### Pharmacodynamic endpoints: insulin tolerance test and mixed meal test

> “A short insulin tolerance test (ITT) was implemented in the 3- to 9-mg/kg dose cohorts at baseline and postinfusion.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

> “Changes in insulin and glucose were monitored through the use of Mixed meal tests (MMTs) and insulin tolerance tests (ITT).”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Interim count at the March 2015 presentation

> “The Phase 1 first-in-human study enrolled 19 healthy volunteer subjects; 14 received XOMA 358 and 5 received placebo.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

> “Results of the study, in which 14 healthy volunteers received XOMA 358 and 5 received placebo, showed XOMA 358 reduced insulin sensitivity and decreased glucose disposal after exogenous insulin injection.”

Source: [XOMA Form 10-Q (2015)](https://www.sec.gov/Archives/edgar/data/791908/000156459015009798/xoma-10q_20150930.htm)

<a id="topic-3.1.5.7.1-2"></a>

##### Healthy volunteer count across phase 1 studies stated in the RIZE publication

> “In previous clinical studies, including two phase 1 single-ascending-dose studies in adult healthy volunteers (n = 22), a combined single-ascending and repeat-dose phase 2 study in adult patients with post-gastric bypass hypoglycemia (n = 16), and two single-ascending-dose phase 2 studies in teen and adult participants with cHI (n = 14), ersodetug was found to be generally safe and well tolerated and resulted in pharmacokinetic (PK) and pharmacodynamic (PD) profiles that support weekly, bi-weekly, and potentially monthly dosing of ersodetug.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

Additional sources: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Pharmacokinetics: dose-proportional exposure and half-life

> “X358 exhibited dose-proportional PK with a half-life of 21 days.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.3-2"></a>

##### Pharmacodynamics: insulin as a biomarker of exposure and reduced insulin sensitivity

> “Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure. X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels. In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.”
> “Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.3-3"></a>

##### Pharmacodynamics at the interim presentation: postprandial glucose and insulin challenge

> “Dose-related increases in post-prandial (after eating a meal) glucose levels, consistent with down-regulation of insulin signaling, were observed through Day 6 following drug infusion, with the Day 3 glucose AUC nearly 80% greater than placebo at the 1 mg/kg dose level. Fasting HOMA-IR values, a measure of reduced insulin signaling, were likewise elevated in a dose-dependent manner and, at peak time points, were several fold over baseline.”
> “Prior to administration of the drug, as expected, the infusion caused a significant lowering of blood sugar. This lowering of blood sugar was significantly blunted at all subsequent time points tested.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### No deaths, serious adverse events, or discontinuations due to adverse events

> “There were no deaths, serious adverse events (AEs), or subject discontinuations due to AEs. There were no clinically meaningful safety findings.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-3.1.5.8.5-2"></a>

##### Tolerability at the interim presentation

> “XOMA 358 appeared to be well-tolerated; there were no serious adverse events.”

Source: [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo)

<a id="topic-3.1.5.8.5-3"></a>

##### Clinical testing limited to single-dose studies in adults after phase 1

> “Based on our interactions with the FDA, XOMA 358 clinical testing is currently limited to single-dose studies in adults.  Data has been generated which will be submitted to request expanded testing as part of our clinical development plan.”

Source: [XOMA Form 10-K (2016)](https://www.sec.gov/Archives/edgar/data/791908/000156459016014295/xoma-10k_20151231.htm)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

- The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
- Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/); [XOMA (2015)](https://investors.xoma.com/news-events/press-releases/detail/267/xoma-presents-positive-phase-1-xoma-358-data-at-the-endo); [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
